Cetuximab and trastuzumab have shown limited efficacy in causing remission in a proportion of patients with metastatic colorectal cancer and breast cancer respectively [21,22], while trastuzumab has improved survival of women with ErbB2 positive breast cancer when given as adjuvant therapy after chemotherapy [32-34]. Here, ERBB2 is linked to breast cancer.